Jump Financial’s Inhibrx INBX Stock Holding History

Jump Financial’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.97M	Buy	29,300 +25,796	+736%	+$1.91M	0.03%	657
2025 Q4	$277K	Buy	+3,504	New	+$239K	﹤0.01%	1598

Other funds holding INBX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jump Financial's INBX Position: Q1 2026 in Review

Jump Financial increased its Inhibrx (INBX) stake by 736% in Q1 2026, buying an estimated $1.91M and bringing the position to 29,300 shares worth $1.97M. The position accounts for 0.03% of the portfolio, ranked #657.

Jump Financial first reported a position in INBX in Q4 2025 and has held it in 2 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

Jump Financial held 29,300 shares of Inhibrx worth $1.97M as of Q1 2026.
Jump Financial bought 25,796 Inhibrx shares in Q1 2026, an estimated $1.91M.
Inhibrx made up 0.03% of Jump Financial's portfolio in Q1 2026, its #657 holding.
Jump Financial first reported a position in Inhibrx in Q4 2025 and has held it in 2 quarters since.
135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.